Indication

Refractory oropharyngeal candidiasis

Refractory oropharyngeal candidiasis is a persistent or recurrent fungal infection of the oral and pharyngeal mucosa that fails to respond clinically to standard first-line antifungal therapy, typically oral fluconazole or itraconazole. Read more about Refractory oropharyngeal candidiasis

3 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Refractory oropharyngeal candidiasis therapies.

Showing 1–3 of 3 drugs

POSACONAZOLE

ANTIFUNGALS-SYSTEMIC·OROPHARYNGEAL CANDIDIASIS·+3
Hikma Pharmaceuticals USA
Filter & compare in the drug finder →Opens the drug finder with Refractory oropharyngeal candidiasis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Refractory oropharyngeal candidiasis.

Refractory oropharyngeal candidiasis is a persistent or recurrent fungal infection of the oral and pharyngeal mucosa that fails to respond clinically to standard first-line antifungal therapy, typically oral fluconazole or itraconazole.

Most commonly affecting severely immunocompromised populations—such as individuals with advanced HIV/AIDS, hematologic malignancies, or profound chemotherapy-induced immunosuppression—the condition is typically caused by *Candida albicans* or non-*albicans Candida* species demonstrating intrinsic or acquired antifungal resistance.

Clinically, it presents with painful, persistent erythema or pseudomembranous white mucosal plaques that can lead to severe dysgeusia, odynophagia, and impaired oral intake, necessitating alternative systemic antifungal management.

Personalize your experience

Follow Refractory oropharyngeal candidiasis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it